...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance
【24h】

CYP2C8- and CYP3A-Mediated C-Demethylation of (3-{[(4-tert-Butylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic Acid (CP-533,536), an EP2 Receptor-Selective Prostaglandin E2 Agonist: Characterization of Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and Liquid Chromatography/Mass Spectrometry-Nuclear Magnetic Resonance

机译:CYP2C8和CYP3A介导的(2- {3-{[(4-叔丁基苄基)-(吡啶-3-磺酰基)-氨基]-甲基}-苯氧基)-乙酸(CP-533,536)的C-去甲基化受体选择性前列腺素E2激动剂:代谢物的高分辨率液相色谱-串联质谱和液相色谱/质谱-核磁共振表征

获取原文
获取原文并翻译 | 示例

摘要

CP-533,536, (3-{[(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid (1), an EP2 receptor-selective prostaglandin E2 agonist, is being developed to aid in the healing of bone fractures. To support the development of this program, in vitro metabolism of 1 was investigated in human liver microsomes and major recombinant human cytochrome P450 (P450) isoforms. 1 was metabolized in vitro by at least three recombinant human P450s: CYP3A4, CYP3A5, and CYP2C8. The turnover of 1 was NADPH-dependent and was completely inhibited by ketoconazole and quercetin in the CYP3A4/5 and CYP2C8 incubations, respectively. The major metabolic pathways were caused by oxidation of the tert-butyl moiety to form the omega-hydroxy metabolite (M4), oxidation of the pyridine moiety, and/or N-dealkylation of the methylphenoxy acetic acid moiety. The alcohol metabolite M4 was further oxidized to the corresponding carboxylic acid M3. In addition to these pathways, three unusual metabolites (M22, M23, and M26) resulting from C-demethylation of the tert-butyl group were identified using high-resolution liquid chromatography/tandem mass spectrometry and liquid chromatography/mass spectrometry/NMR. The C-demethylated metabolites were not detected on incubation of carboxylic acid metabolite M3 with either human liver microsomes or CYP3A/2C8 isoforms, suggesting that these metabolites were not derived from decarboxylation of M3. A possible mechanism for C-demethylation may involve the oxidation of M4 to form an aldehyde metabolite (M24), followed by P450-mediated deformylation, to give an unstable carbon-centered radical and formic acid. The carbon-centered radical intermediate then undergoes either oxygen rebound to form an alcohol metabolite M23 or hydrogen abstraction leading to an olefin metabolite M26.
机译:CP-533,536,(3-{[((4-叔丁基-苄基)-(吡啶-3-磺酰基)-氨基]-甲基}-苯氧基)-乙酸(1),EP2受体选择性前列腺素E2激动剂正在开发,以帮助骨折愈合。为了支持该程序的开发,在人肝微粒体和主要的重组人细胞色素P450(P450)亚型中研究了1的体外代谢。 1在体外被至少三种重组人P450代谢:CYP3A4,CYP3A5和CYP2C8。 1的转换是NADPH依赖性的,在CYP3A4 / 5和CYP2C8孵育中分别被酮康唑和槲皮素完全抑制。主要的代谢途径是由叔丁基部分的氧化形成ω-羟基代谢产物(M4),吡啶部分的氧化和/或甲基苯氧基乙酸部分的N-脱烷基化引起的。醇代谢物M4被进一步氧化为相应的羧酸M3。除了这些途径,还使用高分辨率液相色谱/串联质谱和液相色谱/质谱/ NMR鉴定了由叔丁基的C-去甲基化产生的三种异常代谢物(M22,M23和M26)。在将羧酸代谢物M3与人肝微粒体或CYP3A / 2C8同工型孵育后未检测到C-去甲基代谢物,表明这些代谢物并非源自M3的脱羧作用。 C-去甲基化的可能机制可能涉及M4氧化形成醛代谢产物(M24),然后进行P450介导的甲酰基化,从而生成不稳定的以碳为中心的自由基和甲酸。然后,以碳为中心的自由基中间体经历氧回弹以形成醇代谢物M23或夺氢而生成烯烃代谢物M26。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号